Martinez pointed out that Jusvinza and Nimotuzumab were used in the fight against the pandemic to attack inflammation.

Havana, October 22 (RHC)-- The president of the BioCubaFarma business group, Eduardo Martinez has highlighted the role played by Cuba's pharmaceutical industry in controlling the SARS-CoV-2 virus, which caused COVID-19.

He recalled that in the face of the health emergency, a series of drugs were made available to the Ministry of Public Health, firstly with the idea of raising the immunity levels of the population.

Martinez pointed out that it was essential to raise people's defenses, "that is why Biomodulin-T and Nasalferon, for example, were used. The latter was applied to the doctors who helped to face the new coronavirus in other latitudes, and its effectiveness was demonstrated because very few people were infected", he pointed out.

The scientist added that Interferon Alpha and its combination with Gamma were also very effective, which prevented patients from becoming seriously ill and losing their lives.

He said, "We have a great deal of experience in vaccine development. We have production facilities for that purpose, and at first, we had more than 40 variants, but following the literature and the evolution of the pandemic, we focused on five candidates, three of which received authorization for emergency use".

The president of BioCubaFarma commented that with the immunization campaign implemented with the Soberana 02, Soberana Plus, and Abdala vaccines, it is possible to show a high level of vaccination, "hence, among other factors, we have 99.2 percent of recovered from the disease," he emphasized.

He recalled that all the success of Cuba's health system and its biopharmaceutical industry has been achieved amid the tightening of the economic, commercial, and financial blockade imposed by the United States for more than 60 years.